ReviewJournal of clinical medicine2023
Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Eosinophilia and the Heart: Evolving Concepts.Current cardiology reports · 2026Review
- EGPA at Diagnosis: A Comprehensive Single-Center Profile of Laboratory Findings and Clinical Evidence.International journal of molecular sciences · 2026Article
- Eosinophil Extracellular Traps in Health and Disease: From Host Defense to Chronic Inflammation.Biomedicines · 2026Review
- Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study.BMC pulmonary medicine · 2026Article
- Central Retinal Artery Occlusion Induced by Dupilumab: A Unique Manifestation of Eosinophilic Granulomatosis with Polyangiitis.Internal medicine (Tokyo, Japan) · 2026Article
- CT Features of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD): The "Kebab Sign" as a Marker to Support Differential Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- EGPAware: a European Delphi consensus study on red flags for suspicion of eosinophilic granulomatosis with polyangiitis.EULAR rheumatology open · 2026Article
- Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis in a Pediatric Patient.Cureus · 2026Article
- Management Dilemma: Myeloperoxidase (MPO)-Positive Vasculitis in a Patient With Metastatic Malignant Melanoma.Cureus · 2026Article
- Expert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis.Frontiers in immunology · 2026Review
- Healthcare Resource Utilisation and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Analysis of German Insurance Claims Data.Rheumatology and therapy · 2025Article
- Abdominal pain as the sole initial manifestation of ANCA-positive EGPA with myocarditis: a case report and literature review.BMC cardiovascular disorders · 2025Review
- Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review.International journal of molecular sciences · 2025Review
- Kimura Disease With Eosinophilic Granulomatosis With Polyangiitis Successfully Treated by Mepolizumab.Clinical case reports · 2025Article
- Immunological Markers Associated with Skin Manifestations of EGPA.International journal of molecular sciences · 2025Observational
- Dupilumab-induced Eosinophilic Granulomatosis with Polyangiitis Complicated by Peripheral Neuropathic Pain: a Case Report and Literature Review.Journal of clinical immunology · 2025Review
- Immunopathology of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.International journal of molecular sciences · 2025Review
- Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis and Novel Treatment Options Targeting Complement Activation.Life (Basel, Switzerland) · 2025Review
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) causes necrotizing vasculitis and eosinophil-rich granulomatous inflammation in small- to medium-sized vessels, resulting in multiple organ damage. EGPA is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with myeloperoxidase-ANCA detected in approximately one-third of the patients. Conventional treatment of EGPA relies on systemic glucocorticoids (GCs) in combination with cyclophosphamide when poor prognostic factors are present; however, the dilemma between disease control and drug-related adverse effects has long been a challenge. Recent studies have revealed that the genetic background, pathophysiology, and clinical manifestations differ between ANCA-positive and ANCA-negative patients; however, mepolizumab, an interleukin (IL)-5 inhibitor, is effective in both groups, suggesting that the IL-5-eosinophil axis is deeply involved in the pathogenesis of both ANCA-positive and ANCA-negative EGPA. This review summarizes the latest knowledge on the pathophysiology of EGPA and focuses on the roles of eosinophils and ANCA. We then introduce the current treatment recommendations and accumulated evidence for mepolizumab on EGPA. Based on current unmet clinical needs, we discuss potential future therapeutic strategies for EGPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.